Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review)
George Mihai Niţulescu, Horia Păunescu, Sterghios Moschos, et al.
International Journal of Molecular Medicine (2020) Vol. 46, Iss. 2, pp. 467-488
Open Access | Times Cited: 133

Showing 26-50 of 133 citing articles:

Zinc and SARS‑CoV‑2: A molecular modeling study of Zn interactions with RNA‑dependent RNA‑polymerase and 3C‑like proteinase enzymes
Ali Pormohammad, Nadia K. Monych, Raymond J. Turner
International Journal of Molecular Medicine (2020) Vol. 47, Iss. 1, pp. 326-334
Open Access | Times Cited: 48
A dissection of SARS‑CoV2 with clinical implications (Review)
Felician Stancioiu, Georgios Papadakis, Stelios Kteniadakis, et al.
International Journal of Molecular Medicine (2020) Vol. 46, Iss. 2, pp. 489-508
Open Access | Times Cited: 43
COVID‐19 breakthroughs: separating fact from fiction
Paraminder Dhillon, Manuel Breuer, Natasha Hirst
FEBS Journal (2020) Vol. 287, Iss. 17, pp. 3612-3632
Open Access | Times Cited: 41
The bumpy road to achieve herd immunity in COVID-19
Monica Neagu
Journal of Immunoassay and Immunochemistry (2020) Vol. 41, Iss. 6, pp. 928-945
Open Access | Times Cited: 41
Is Nanotechnology Helping in the Fight Against COVID-19?
Valéria Maria de Oliveira Cardoso, Bruna Juliana Moreira, Edson José Comparetti, et al.
Frontiers in Nanotechnology (2020) Vol. 2
Open Access | Times Cited: 40
Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein
Shweta Alai, Nidhi Gujar, Manali Joshi, et al.
Heliyon (2021) Vol. 7, Iss. 3, pp. e06564-e06564
Open Access | Times Cited: 32
Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals
Jiaman Du, Jiewen Fu, Wenqian Zhang, et al.
International Journal of Oncology (2023) Vol. 62, Iss. 3
Open Access | Times Cited: 13
Nutraceuticals and Their Contribution to Preventing Noncommunicable Diseases
Aurora de Jesús Garza-Juárez, Esther Pérez‐Carrillo, Eder Arredondo‐Espinoza, et al.
Foods (2023) Vol. 12, Iss. 17, pp. 3262-3262
Open Access | Times Cited: 12
Unraveling the roles of vitamin D status and melanin during Covid‑19 (Review)
Polytimi Sidiropoulou, Anca Oana Docea, Vasiliki Nikolaou, et al.
International Journal of Molecular Medicine (2020) Vol. 47, Iss. 1, pp. 92-100
Open Access | Times Cited: 32
COVID‐19: Risk Factors Associated with Infectivity and Severity
Nahla Fadl, Esraa Ali, Tamer Z. Salem
Scandinavian Journal of Immunology (2021) Vol. 93, Iss. 6
Open Access | Times Cited: 29
Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management
Debmalya Barh, Alaa A. A. Aljabali, Murtaza M. Tambuwala, et al.
Biomedicines (2021) Vol. 9, Iss. 5, pp. 556-556
Open Access | Times Cited: 29
Combination therapies for COVID‐19: An overview of the clinical trials landscape
Sola Akinbolade, Diarmuid Coughlan, Ross Fairbairn, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 4, pp. 1590-1597
Open Access | Times Cited: 29
Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection
Natasja de Bruin, Ann‐Kathrin Schneider, Philipp Reus, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1049-1049
Open Access | Times Cited: 19
Deciphering the Intricacies of Immune System Dysfunction and its Impact on Diabetes Mellitus: Revisiting the Communication Strategies to Manage Diabetes Mellitus
Vaibhav, Saikh Shireen Nishad, Dipali Barku Dongare, et al.
Health Sciences Review (2024) Vol. 13, pp. 100201-100201
Open Access | Times Cited: 3
The value of serum amyloid A for predicting the severity and recovery of COVID‑19
Jun Fu, Pianpian Huang, Shuang Zhang, et al.
Experimental and Therapeutic Medicine (2020)
Open Access | Times Cited: 31
The under-reported role of toxic substance exposures in the COVID-19 pandemic
Ronald N. Kostoff, Michael B. Briggs, Alan L. Porter, et al.
Food and Chemical Toxicology (2020) Vol. 145, pp. 111687-111687
Open Access | Times Cited: 31
Advances in the computational landscape for repurposed drugs against COVID-19
Illya Aronskyy, Yosef Masoudi-Sobhanzadeh, Antonio Cappuccio, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 12, pp. 2800-2815
Open Access | Times Cited: 26
Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells
Ria Goswami, Veronica Russell, Joshua J. Tu, et al.
iScience (2021) Vol. 24, Iss. 12, pp. 103412-103412
Open Access | Times Cited: 26
Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic
Syed Mohammed Basheeruddin Asdaq, Abu Md Ashif Ikbal, Ram Kumar Sahu, et al.
Nanomaterials (2021) Vol. 11, Iss. 7, pp. 1841-1841
Open Access | Times Cited: 25
Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
Sijia Tao, Keivan Zandi, Leda Bassit, et al.
Current Research in Pharmacology and Drug Discovery (2021) Vol. 2, pp. 100045-100045
Open Access | Times Cited: 25
SARS-CoV-2 Spreads through Cell-to-Cell Transmission
Cong Zeng, John P. Evans, Tiffany King, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 23
A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2)
Paolo Coghi, Li Yang, Jerome P. L. Ng, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 10, pp. 954-954
Open Access | Times Cited: 23
Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection
Mostafa Akbarzadeh-Khiavi, Mitra Torabi, Leila Rahbarnia, et al.
Infection (2021) Vol. 50, Iss. 2, pp. 295-308
Open Access | Times Cited: 23
DRaW: prediction of COVID-19 antivirals by deep learning—an objection on using matrix factorization
Seyyed Morteza Hashemi, Arash Zabihian, Mohsen Hooshmand, et al.
BMC Bioinformatics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study
G. Lizbeth Ramírez-Salinas, Marlet Martínez‐Archundia, José Correa‐Basurto, et al.
Molecules (2020) Vol. 25, Iss. 23, pp. 5615-5615
Open Access | Times Cited: 26

Scroll to top